View Risk


Article data
Xu (2020)
Risk factors for adverse clinical outcomes with COVID-19 in China - a multicenter, retrospective, observational study.pdf
https://dx.doi.org/10.7150%2Fthno.46833
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255028/

Results
Complications
Leukocytosis (Present vs. Not present)
COVID-19 (death)
Hazard ratio: 9.639 (4.572-20.321) Adjusted model

Study characteristics

China

Retrospective observational study

Medical records

703

We systematically analyzed the clinical, laboratory and CT imaging data of laboratory confirmed COVID-19 patients with clear prognostic information in 16 tertiary hospitals from 8 provinces, including 5 of the top 10 provinces - that is, Hubei Province, Zhejiang Province, Anhui Province, Shandong Province, and Jiangsu Province of China between January 10, 2020 and March 13, 2020 and identified the risk factors associated with in-hospital death as well as adverse outcomes.

This study included 703 laboratory-confirmed patients with a mean age of 46.1 years (SD 15.2) (range from 2 months to 86 years old), and 382 (54%) were males, 321 (46%) were females. Of the entire cohort, 648 (92%) discharged without any adverse outcome (stable group), 55 (8%) patients developed adverse clinical outcomes (adverse group), of whom 46 (84%) were admitted to the ICU and 20 (36%) required IMV besides death. The median time (IQR) interval between admission and discharge/adverse outcomes was 16 (11-20) days. At data cutoff, 659 of the total 703 patients (94%) were discharged from the hospital, 33 patients (5%) died, and the remaining 11 patients (2%) were still hospitalized in ICU.

Median

14 Day


Results

COVID-19 (death)

33

in-hospital death

Complications

Leukocytosis

Leukocytosis is a condition in which the white cell (leukocyte count) is above the normal range in the blood.

Not present

Present

Hazard ratio

9.639 (4.572-20.321)

No

Yes

Yes

Risk adjusted for In-hospital Death and Adverse Outcomes. i) In-hospital Death : >=2 comorbidities, leukocytosis, lymphopenia, CT severity score. ii) Adverse Outcomes : Age, >=2 comorbidities, leukocytosis, lymphopenia, CT severity score.


Other information

The primary endpoint was in-hospital death, the secondary endpoints were composite clinical adverse outcomes including in-hospital death, admission to intensive care unit (ICU) and requiring invasive mechanical ventilation support (IMV).

Average

Yes

Go Back